Wolverine Asset Management LLC Takes Position in Emergent BioSolutions Inc. (NYSE:EBS)

Wolverine Asset Management LLC purchased a new stake in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 136,333 shares of the biopharmaceutical company's stock, valued at approximately $1,303,000. Wolverine Asset Management LLC owned 0.25% of Emergent BioSolutions at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Stifel Financial Corp acquired a new position in shares of Emergent BioSolutions during the 3rd quarter worth $96,000. FORA Capital LLC bought a new position in shares of Emergent BioSolutions in the third quarter worth about $103,000. Landscape Capital Management L.L.C. bought a new position in shares of Emergent BioSolutions in the third quarter worth about $141,000. Entropy Technologies LP acquired a new stake in shares of Emergent BioSolutions in the 3rd quarter valued at approximately $155,000. Finally, Hussman Strategic Advisors Inc. bought a new stake in shares of Emergent BioSolutions during the 4th quarter valued at approximately $201,000. Institutional investors and hedge funds own 78.40% of the company's stock.

Analysts Set New Price Targets

EBS has been the subject of a number of research reports. Benchmark increased their price target on Emergent BioSolutions from $8.00 to $12.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. HC Wainwright reiterated a "buy" rating and issued a $15.00 target price on shares of Emergent BioSolutions in a research report on Tuesday, January 21st. Finally, StockNews.com upgraded Emergent BioSolutions from a "hold" rating to a "buy" rating in a report on Monday, February 17th.

Remove Ads

Emergent BioSolutions Stock Up 0.5 %

Shares of Emergent BioSolutions stock traded up $0.04 during trading on Wednesday, reaching $7.25. 699,040 shares of the company traded hands, compared to its average volume of 1,040,967. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47. The firm has a market capitalization of $392.56 million, a PE ratio of -1.77 and a beta of 1.62. The company has a 50 day moving average price of $9.59 and a 200-day moving average price of $9.08. Emergent BioSolutions Inc. has a 1-year low of $1.82 and a 1-year high of $15.10.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.